| Outcome Measures: |
Primary: Primary efficacy endpoint (Cerebral Glucose Metabolic Rate), Change in Cerebral glucose metabolic rate \& MRI Measures of Cerebral Volumetric and functional changes and white matter structural and functional connectivity as measured by Fluorodeoxyglucose Positron Emission Tomography \& 3T MRI (FDG-PET/MRI) scans at Baseline and at 2 years., 2 years|Primary cognitive endpoint (Neuropsychological Performance), Change in Composite z-score of memory and multi-domain non-amnestic cognitive test performance using a Neuropsychological Assessment performed at Baseline and at 2 years., 2 years | Secondary: Secondary clinical endpoints Subjective Memory and Cognitive Complaint (SMCC, Change in Subjective Memory and Cognitive Complaint (SMCC) as measured at baseline and at 2 years., 2 years|Secondary clinical endpoints Basic Activities of Daily Liver (ADL), Change in Basic Activities of Daily Liver (ADL) as measured at baseline and at 2 years., 2 years|Secondary clinical endpoints Cognitive Instrumental Activities of Daily Living Scale, Change in Cognitive Instrumental Activities of Daily Living Scale (Cog-IADL) as measured at baseline and at 2 years., 2 years|Secondary clinical endpoints Global Clinical Dementia Rating Sum of Boxes, Change in Global Clinical Dementia Rating Sum of Boxes (version with Informant and version without need for Informant- CDR-SB) as measured at baseline and at 2 years., 2 years|Secondary clinical endpoints Mini-Mental State Examination, Change in Mini-Mental State Examination \[MMSE\]as measured at baseline and at 2 years., 2 years|Secondary clinical endpoints Montreal Cognitive Assessment scale, Change in Montreal Cognitive Assessment scale \[MoCA\] as measured at baseline and at 2 years., 2 years|Secondary adherence endpoints fasting plasma insulin, Markers of lowered insulin resistance (Change in fasting plasma insulin) as measured at baseline and at 2 years., 2 years|Secondary adherence endpoints Homeostatic Model Assessment (HOMA), Markers of lowered insulin resistance \[Change in Homeostatic Model Assessment (HOMA)\] as measured at baseline and at 2 years., 2 years|Secondary adherence endpoints Lifestyle Intervention (Change in Weight), Lifestyle Intervention (Change in Weight) as measured at baseline and at 2 years., 2 years|Secondary adherence endpoints Body Mass Index, Lifestyle Intervention \[Change in Body Mass Index (BMI)\] as measured at baseline and at 2 years., 2 years|Secondary adherence endpoints Waist Circumference, Lifestyle Intervention (Change in Waist Circumference) as measured at baseline and at 2 years., 2 years|Secondary adherence endpoints Fasting plasma glucose, Glycemic Control (Change in Fasting plasma glucose) as measured at baseline and at 2 years., 2 years|Secondary adherence endpoints Glycated Hemoglobin (HbA1c), Glycemic Control \[Change in Glycated Hemoglobin (HbA1c)\] as measured at baseline and at 2 years., 2 years|Secondary adherence endpoints Fasting Lipids, Metabolic control \[Change in Fasting Lipids (total cholesterol, HDL-Chol, LDL-Chol, triglycerides)\] as measured at baseline and at 2 years., 2 years
|
